CVAS-an interesting california-based biotech company here Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVAS-an interesting california-based biotech company here

CVAS 0.000400

0.0%

Oct 7 9:32 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (73)	11/14/2001 10:03:58 AM
From: tuck	Read Replies (1) of 126

>>SAN DIEGO, Nov. 14 /PRNewswire/ -- Corvas International, Inc. (Nasdaq: CVAS - news) today announced that enrollment in the multi-center Phase IIb study of UK-279,276 (formerly known as neutrophil inhibitory factor, or rNIF) being conducted by Pfizer Inc (NYSE: PFE - news) has been completed in accordance with the study protocol design. The primary goal of the study is to determine the dose-response relationship of UK-279,276 for efficacy and toleration in patients suffering from ischemic stroke. The protocol includes a three-month follow-up period following which the data will be analyzed. Conclusions cannot be drawn regarding the outcome of this study until all patients have been fully evaluated and the resulting data have been extensively analyzed. The final results from this trial will be reported following complete data analysis. Corvas has a strategic alliance with Pfizer for the development and commercialization of UK-279,276.<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next